GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Miels will formally assume the role on January 1, 2026
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
The company is bringing precision therapies for gynaecological cancers
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Subscribe To Our Newsletter & Stay Updated